Profile data is unavailable for this security.
About the company
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
- Revenue in USD (TTM)173.48m
- Net income in USD-16.54m
- Incorporated1977
- Employees426.00
- LocationAxoGen IncSUITE 100, 13859 PROGRESS BLVD.ALACHUA 32615United StatesUSA
- Phone+1 (386) 462-6817
- Fax+1 (386) 462-6801
- Websitehttps://www.axogeninc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Varex Imaging Corp | 832.70m | 34.20m | 444.99m | 2.30k | 23.79 | 0.7649 | 6.54 | 0.5344 | 0.4574 | 0.4574 | 16.46 | 14.22 | 0.6758 | 1.95 | 5.28 | 346,958.30 | 2.82 | 0.9913 | 3.33 | 1.18 | 32.16 | 31.70 | 4.17 | 1.36 | 1.89 | 2.00 | 0.4271 | -- | 3.96 | 2.93 | 59.08 | 18.88 | 0.2924 | -- |
| MaxCyte Inc | 45.44m | -35.43m | 457.49m | 143.00 | -- | 2.06 | -- | 10.07 | -0.3408 | -0.3408 | 0.437 | 2.11 | 0.1739 | 0.4741 | 7.46 | 317,762.90 | -13.56 | -13.18 | -14.25 | -14.33 | 88.43 | 88.79 | -77.97 | -62.96 | 13.40 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| ZimVie Inc | 453.38m | -54.86m | 467.62m | 2.60k | -- | 1.19 | -- | 1.03 | -2.04 | -13.27 | 16.84 | 14.29 | 0.3858 | 1.12 | 3.80 | 174,378.50 | -4.67 | -- | -5.43 | -- | 63.11 | 65.51 | -12.10 | -8.73 | 1.43 | -0.3884 | 0.3737 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Pacific Biosciences of California Inc | 188.87m | -400.38m | 555.96m | 796.00 | -- | 1.13 | -- | 2.94 | -1.50 | -1.50 | 0.7099 | 1.81 | 0.1125 | 2.05 | 6.69 | 237,275.10 | -23.85 | -16.19 | -26.63 | -17.81 | 26.01 | 37.35 | -211.99 | -136.21 | 7.14 | -22.46 | 0.6444 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Surmodics Inc | 120.82m | -1.40m | 557.71m | 376.00 | -- | 4.76 | 76.26 | 4.62 | -0.0955 | -0.0955 | 8.55 | 8.28 | 0.6597 | 2.09 | 5.64 | 321,332.40 | -0.7638 | -1.85 | -0.8909 | -2.18 | 74.02 | 82.93 | -1.16 | -2.98 | 3.22 | -4.46 | 0.1999 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Paragon 28 Inc | 235.44m | -59.07m | 574.51m | 430.00 | -- | 3.91 | -- | 2.44 | -0.7132 | -0.7132 | 2.84 | 1.76 | 0.7703 | 0.6049 | 6.63 | 547,539.60 | -19.33 | -- | -23.48 | -- | 76.67 | -- | -25.09 | -- | 1.70 | -5.30 | 0.4295 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| Quanterix Corp | 129.33m | -39.71m | 594.49m | 441.00 | -- | 1.77 | -- | 4.60 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Orthofix Medical Inc | 771.65m | -120.49m | 611.73m | 1.63k | -- | 1.14 | -- | 0.7928 | -3.21 | -3.21 | 20.55 | 14.35 | 0.8654 | 1.17 | 6.49 | 472,245.40 | -13.51 | -8.88 | -16.22 | -10.96 | 67.18 | 72.37 | -15.62 | -9.28 | 1.13 | -4.94 | 0.2005 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Iradimed Corp | 69.48m | 18.64m | 623.73m | 148.00 | 33.65 | 7.83 | 32.04 | 8.98 | 1.46 | 1.46 | 5.45 | 6.29 | 0.8109 | 1.55 | 6.03 | 469,485.30 | 21.76 | 13.16 | 23.85 | 14.58 | 77.21 | 76.55 | 26.83 | 21.46 | 8.25 | 144.05 | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| AxoGen Inc | 173.48m | -16.54m | 642.98m | 426.00 | -- | 6.72 | -- | 3.71 | -0.3829 | -0.3829 | 4.01 | 2.18 | 0.9117 | 1.62 | 7.43 | 407,237.10 | -8.69 | -13.92 | -9.93 | -15.84 | 76.98 | 79.74 | -9.53 | -20.28 | 2.32 | -2.94 | 0.3297 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Simulations Plus Inc | 66.98m | 9.65m | 645.45m | 192.00 | 68.05 | 3.57 | 45.64 | 9.64 | 0.474 | 0.474 | 3.29 | 9.04 | 0.3603 | -- | 5.57 | 348,843.80 | 5.19 | 7.20 | 5.49 | 7.61 | 72.53 | 77.61 | 14.40 | 21.29 | -- | -- | 0.00 | 45.70 | 10.52 | 14.96 | -20.20 | 6.02 | 12.91 | 0.8548 |
| SI-Bone Inc | 150.71m | -40.85m | 660.02m | 344.00 | -- | 3.99 | -- | 4.38 | -1.00 | -1.00 | 3.70 | 3.97 | 0.6586 | 1.54 | 6.67 | 438,107.60 | -17.85 | -27.88 | -19.57 | -30.94 | 77.69 | 85.03 | -27.10 | -51.09 | 8.12 | -- | 0.18 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Mesa Laboratories Inc | 223.71m | -250.31m | 694.70m | 736.00 | -- | 4.61 | -- | 3.11 | -46.43 | -46.43 | 41.43 | 27.87 | 0.4131 | 2.51 | 6.29 | 303,956.50 | -46.23 | -9.20 | -50.62 | -9.88 | 62.27 | 60.60 | -111.89 | -28.33 | 1.37 | 1.33 | 0.5848 | -- | -1.32 | 15.95 | -27,438.28 | -- | 15.26 | 0.00 |
| Cytek Biosciences Inc | 197.71m | -17.56m | 695.66m | 645.00 | -- | 1.79 | -- | 3.52 | -0.1327 | -0.1327 | 1.49 | 2.96 | 0.392 | 1.54 | 4.19 | 292,470.40 | -3.48 | -- | -3.89 | -- | 54.97 | -- | -8.88 | -- | 6.38 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Orthopediatrics Corp | 175.07m | -25.12m | 707.30m | 247.00 | -- | 1.91 | -- | 4.04 | -1.10 | -1.10 | 7.65 | 15.33 | 0.4045 | 0.4286 | 4.61 | 708,793.50 | -5.80 | -5.40 | -6.43 | -5.93 | 74.62 | 75.09 | -14.35 | -15.92 | 1.96 | -44.23 | 0.0261 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
| Standard Biotools Inc | 136.30m | -164.66m | 783.14m | 534.00 | -- | 1.53 | -- | 5.75 | -0.9018 | -0.9018 | 0.6606 | 1.37 | 0.2561 | 2.25 | 5.73 | 255,243.50 | -22.29 | -28.17 | -26.55 | -33.60 | 46.67 | 51.58 | -87.05 | -74.85 | 3.53 | -- | 0.0974 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
Data as of Sep 19 2024. Currency figures normalised to AxoGen Inc's reporting currency: US Dollar USD
53.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ArrowMark Colorado Holdings LLCas of 30 Jun 2024 | 5.12m | 11.67% |
| First Light Asset Management LLCas of 30 Jun 2024 | 3.34m | 7.63% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 3.31m | 7.54% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.90m | 6.62% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.44m | 5.57% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.33m | 5.31% |
| Assenagon Asset Management SA (Germany)as of 30 Jun 2024 | 1.31m | 2.99% |
| Geode Capital Management LLCas of 30 Jun 2024 | 978.90k | 2.23% |
| DAFNA Capital Management LLCas of 30 Jun 2024 | 935.89k | 2.14% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 801.62k | 1.83% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
